Derik De Bruin
Stock Analyst at B of A Securities
(4.62)
# 212
Out of 4,918 analysts
217
Total ratings
65.75%
Success rate
15.62%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVTY Revvity | Maintains: Buy | $116 → $110 | $88.32 | +24.55% | 3 | Jun 26, 2025 | |
| BRKR Bruker | Maintains: Buy | $61 → $50 | $34.72 | +44.03% | 13 | Jun 26, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $13 | $13.68 | -4.97% | 9 | Jun 26, 2025 | |
| QGEN Qiagen | Maintains: Buy | $50 → $53 | $50.25 | +5.47% | 6 | Jun 26, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,200 → $1,260 | $1,231.88 | +2.28% | 10 | Jun 26, 2025 | |
| WAT Waters | Maintains: Neutral | $370 → $375 | $285.59 | +31.31% | 14 | Jun 26, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $156 → $128 | $114.84 | +11.46% | 33 | Apr 14, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $3.98 | +176.38% | 13 | Mar 3, 2025 | |
| EXAS Exact Sciences | Maintains: Buy | $72 → $65 | $46.83 | +38.80% | 7 | Feb 20, 2025 | |
| NEO NeoGenomics | Maintains: Neutral | $19 → $16 | $5.67 | +182.19% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $675 → $660 | $466.57 | +41.46% | 18 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $255 → $235 | $182.75 | +28.59% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $220 → $210 | $167.92 | +25.06% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $355 | $238.39 | +48.92% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $25.58 | +1.64% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $263.85 | +2.71% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $172.44 | +5.54% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $290 | $197.46 | +46.87% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $13 → $15 | $27.14 | -44.73% | 4 | Aug 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $6.42 | +227.10% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $19.99 | +60.08% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $98.44 | +1.58% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $67.91 | +26.64% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $3.88 | +235.05% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $2.13 | +205.16% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $164.80 | +57.77% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $13.60 | +782.35% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $151.81 | -20.95% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $1.65 | +445.45% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $682.78 | -65.58% | 3 | Nov 2, 2018 |
Revvity
Jun 26, 2025
Maintains: Buy
Price Target: $116 → $110
Current: $88.32
Upside: +24.55%
Bruker
Jun 26, 2025
Maintains: Buy
Price Target: $61 → $50
Current: $34.72
Upside: +44.03%
10x Genomics
Jun 26, 2025
Maintains: Neutral
Price Target: $12 → $13
Current: $13.68
Upside: -4.97%
Qiagen
Jun 26, 2025
Maintains: Buy
Price Target: $50 → $53
Current: $50.25
Upside: +5.47%
Mettler-Toledo International
Jun 26, 2025
Maintains: Neutral
Price Target: $1,200 → $1,260
Current: $1,231.88
Upside: +2.28%
Waters
Jun 26, 2025
Maintains: Neutral
Price Target: $370 → $375
Current: $285.59
Upside: +31.31%
Agilent Technologies
Apr 14, 2025
Maintains: Neutral
Price Target: $156 → $128
Current: $114.84
Upside: +11.46%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $3.98
Upside: +176.38%
Exact Sciences
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $46.83
Upside: +38.80%
NeoGenomics
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $5.67
Upside: +182.19%
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $466.57
Upside: +41.46%
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $182.75
Upside: +28.59%
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $167.92
Upside: +25.06%
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $238.39
Upside: +48.92%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $25.58
Upside: +1.64%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $263.85
Upside: +2.71%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $172.44
Upside: +5.54%
Dec 13, 2024
Upgrades: Buy
Price Target: $290
Current: $197.46
Upside: +46.87%
Aug 30, 2024
Maintains: Underperform
Price Target: $13 → $15
Current: $27.14
Upside: -44.73%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $6.42
Upside: +227.10%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $19.99
Upside: +60.08%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $98.44
Upside: +1.58%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $67.91
Upside: +26.64%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $3.88
Upside: +235.05%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $2.13
Upside: +205.16%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $164.80
Upside: +57.77%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $13.60
Upside: +782.35%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $151.81
Upside: -20.95%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $1.65
Upside: +445.45%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $682.78
Upside: -65.58%